Resource center

We're excited to launch Off Protocol, a podcast that challenges the status quo of clinical trials and explores the realities of clinical research.

For decades, women have been underrepresented in clinical trials — a gap that’s not just unfortunate but dangerous. When research isn’t representative of half the global population, we can’t truly develop treatments that are safe and effective for all.

Finding patients for clinical trials is only half the battle. True clinical trial success comes from clear communication, personalisation, and keeping participants engaged.

Ovarian cancer remains one of the most lethal gynecological cancers, largely because diagnosis often comes too late. Around 70% of cases are detected at an advanced stage, with approximately 300,000 new cases each year.

Deciding which trial activities to manage internally and when to engage a diagnostics-focused CRO can significantly impact timelines, data quality, and ultimately, market success.

In oncology diagnostics, selecting between biobank specimens and prospective clinical trials for assay validation is not merely a methodological choice—it’s a strategic imperative.

For sponsors developing rapid infectious disease diagnostics, the landscape is shifting fast. Traditional lab tests take hours or days, but rapid diagnostics deliver results in minutes. This shift creates a significant challenge: clinical trial strategies designed for slow, centralized tests won’t work for fast, decentralized ones.

Cancer diagnostics are entering a pivotal era, with advances in genomics, AI, and non-invasive testing reshaping how and when we detect disease.

Psychedelics are reshaping mental health treatment, with over 100 active psilocybin trials reflecting renewed interest after decades of stalled progress due to stigma and regulation.

From insulin to immunotherapies, clinical trials have powered some of the most important medical breakthroughs of our time.